Ditchcarbon
  • Contact
  1. Organizations
  2. ALX Oncology Holdings Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

ALX Oncology Holdings Inc. Sustainability Profile

Company website

ALX Oncology Holdings Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 2015, the company focuses on developing innovative therapies for cancer treatment, particularly through its expertise in immune-oncology. ALX Oncology is renowned for its lead product candidate, ALX148, which is designed to enhance the immune response against tumours by targeting the CD47 pathway, a unique approach that sets it apart in the competitive landscape. With a strong operational presence in key regions, ALX Oncology has made significant strides in clinical development, achieving notable milestones that underscore its commitment to advancing cancer care. The company’s dedication to pioneering solutions positions it as a leader in the fight against cancer, making substantial contributions to the evolving landscape of oncology therapeutics.

DitchCarbon Score

How does ALX Oncology Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

17

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

ALX Oncology Holdings Inc.'s score of 17 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.

15%

Let us know if this data was useful to you

ALX Oncology Holdings Inc.'s reported carbon emissions

ALX Oncology Holdings Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that ALX Oncology may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for ALX Oncology to establish clear climate commitments and reduction initiatives to align with global standards and expectations.

How Carbon Intensive is ALX Oncology Holdings Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. ALX Oncology Holdings Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is ALX Oncology Holdings Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for ALX Oncology Holdings Inc. is in US, which has a low grid carbon intensity relative to other regions.

ALX Oncology Holdings Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

ALX Oncology Holdings Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare ALX Oncology Holdings Inc.'s Emissions with Industry Peers

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

GeneScience Pharmaceuticals Co., Ltd.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

ImmuneOncia Therapeutics, Inc.

KR
Updated 24 days ago

Novimmune SA

CH
•
Research and development services (73)
Updated 16 days ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy